It has been demonstrated that a randomized placebo-controlled curcumin trial showed decreased liver lipid accumulation and AST and ALT levels in NAFLD patients without resistance [217]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.